U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly ...

Since 2021, there’s been an increase in representation of people from underrepresented and underserved communities in Super ...

The chemical manufacturer affected natural resources to the tune of over $1 billion and contributed to a rise in cancer cases ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Jenny Herman, the Senior Vice President and Controller at Schrodinger, Inc. (NASDAQ:SDGR), recently sold 859 shares of the company's common stock. The shares were sold at a price of $24.43 each, ...